1H-Pyrazole-4-carboxamide, 3-[2-(3,5-dimethoxyphenyl)ethynyl]-5-(methylamino)-1-[(3S)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]-

Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer[1]. Gunagratinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups[1][2].

FGFR

[1] Guo Ye, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4092-4092.
[2] Jisong Cui, et al. Method for treating head and neck cancer. WO2023088105A1. 2022-11-03